Vor Biopharma (VOR) Total Liabilities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Total Liabilities data on file, last reported at $657.2 million in Q1 2026.

• Quarterly Total Liabilities rose 1419.71% year-over-year to $657.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $657.2 million (up 1419.71% YoY) and the FY2025 annual result came in at $628.4 million, up 1259.46% from the prior year.
• Total Liabilities improved to $657.2 million in Q1 2026 per VOR's latest filing, from $628.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $2.4 billion in Q3 2025 and bottomed at $39.8 million in Q1 2022.
• The 5-year median for Total Liabilities is $47.4 million (2023), against an average of $352.6 million.
• The widest annual swing landed in 2024, when Total Liabilities fell 10.79%; it then soared 5480.73% in 2025.
• Tracing VOR's Total Liabilities over 5 years: stood at $48.8 million in 2022, then slipped by 2.78% to $47.4 million in 2023, then slipped by 2.48% to $46.2 million in 2024, then soared by 1259.46% to $628.4 million in 2025, then increased by 4.57% to $657.2 million in 2026.
• Per Business Quant, the three latest VOR Total Liabilities figures stand at $657.2 million (Q1 2026), $628.4 million (Q4 2025), and $2.4 billion (Q3 2025).

Peer Comparison